Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multinational Suitors Queue Up As India's Paras Pharma Valuation Shoots Above $1 Billion

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As prospective multinational suitors queue up to clinch a majority equity stake in Paras Pharma - a fast-growing Indian OTC and cosmetic company - leading investment bankers have questioned whether the asking price is "unreasonable and exaggerated.

You may also be interested in...



Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up

MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years

Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up

MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years

J&J Ties Up With India's Emcure For a Splash Into Branded Generics; Deal May Be Precursor To Bigger Global Presence

MUMBAI - It may be a small start in India but the drugs-to-diagnostics giant Johnson & Johnson looks set for a big splash in branded generic drugs - a segment its bigger rivals like Pfizer, GlaxoSmithKline and Sanofi-Aventis have been embracing over the last few years through aggressive partnerships and acquisition of strong regional players

Latest News
See All
UsernamePublicRestriction

Register

SC073294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel